SG11201900738YA - Gpr156 variants and uses thereof - Google Patents
Gpr156 variants and uses thereofInfo
- Publication number
- SG11201900738YA SG11201900738YA SG11201900738YA SG11201900738YA SG11201900738YA SG 11201900738Y A SG11201900738Y A SG 11201900738YA SG 11201900738Y A SG11201900738Y A SG 11201900738YA SG 11201900738Y A SG11201900738Y A SG 11201900738YA SG 11201900738Y A SG11201900738Y A SG 11201900738YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- gpr156
- aspartic acid
- pct
- protein
- Prior art date
Links
- 101150071692 Gpr156 gene Proteins 0.000 title 1
- 101001039301 Homo sapiens Probable G-protein coupled receptor 156 Proteins 0.000 abstract 4
- 102100041015 Probable G-protein coupled receptor 156 Human genes 0.000 abstract 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 3
- 235000003704 aspartic acid Nutrition 0.000 abstract 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 3
- 208000020401 Depressive disease Diseases 0.000 abstract 2
- 230000004075 alteration Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000003104 endogenous depression Diseases 0.000 abstract 2
- 208000024714 major depressive disease Diseases 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101100505306 Homo sapiens GPR156 gene Proteins 0.000 abstract 1
- -1 cDNA Chemical class 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367973P | 2016-07-28 | 2016-07-28 | |
| PCT/US2017/044321 WO2018022967A1 (en) | 2016-07-28 | 2017-07-28 | Gpr156 variants and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900738YA true SG11201900738YA (en) | 2019-02-27 |
Family
ID=59649989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900738YA SG11201900738YA (en) | 2016-07-28 | 2017-07-28 | Gpr156 variants and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10266582B2 (https=) |
| EP (2) | EP4230648A3 (https=) |
| JP (2) | JP7556688B2 (https=) |
| KR (2) | KR20240027874A (https=) |
| CN (1) | CN109563516B (https=) |
| AU (1) | AU2017302611B2 (https=) |
| CA (1) | CA3032124A1 (https=) |
| DK (1) | DK3491014T5 (https=) |
| IL (1) | IL264473A (https=) |
| MX (2) | MX2019001084A (https=) |
| NZ (1) | NZ751010A (https=) |
| SG (1) | SG11201900738YA (https=) |
| WO (1) | WO2018022967A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7556688B2 (ja) * | 2016-07-28 | 2024-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｇｐｒ１５６変異体及びその使用 |
| CA3074652A1 (en) | 2017-09-06 | 2019-03-14 | Regeneron Pharmaceuticals, Inc. | Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN113423266A (zh) * | 2019-01-17 | 2021-09-21 | 雷杰纳荣制药公司 | 情绪障碍的啮齿动物模型 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5294533A (en) | 1988-07-05 | 1994-03-15 | Baylor College Of Medicine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
| US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
| US5271941A (en) | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
| US5786138A (en) | 1993-01-29 | 1998-07-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Hyperstabilizing antisense nucleic acid binding agents |
| JPH10510700A (ja) | 1993-06-04 | 1998-10-20 | アメリカ合衆国 | アンチセンスオリゴヌクレオチドを用いてカポジ肉腫を治療する方法 |
| US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| US5641754A (en) | 1994-01-10 | 1997-06-24 | The Board Of Regents Of The University Of Nebraska | Antisense oligonucleotide compositions for selectively killing cancer cells |
| EP0775204A1 (en) | 1994-08-09 | 1997-05-28 | Novartis AG | Antitumor antisense oligonucleotides |
| US5856103A (en) | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
| US5994320A (en) | 1995-02-06 | 1999-11-30 | Regents Of The University Of Minnesota | Antisense oligonucleotides and methods for treating central nervous system tumors |
| IT1275862B1 (it) | 1995-03-03 | 1997-10-24 | Consiglio Nazionale Ricerche | Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento |
| US6040296A (en) | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| AU7286696A (en) | 1995-10-13 | 1997-05-07 | F. Hoffmann-La Roche Ag | Antisense oligomers |
| CA2236825A1 (en) | 1995-11-21 | 1997-05-29 | Icn Pharmaceuticals, Inc. | Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor |
| WO1997029757A1 (en) | 1996-02-15 | 1997-08-21 | National Institutes Of Health | Rnase l activators and antisense oligonucleotides effective to treat rsv infections |
| US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
| US6046004A (en) | 1997-02-27 | 2000-04-04 | Lorne Park Research, Inc. | Solution hybridization of nucleic acids with antisense probes having modified backbones |
| JPH1142091A (ja) | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | アンチセンス核酸化合物 |
| US6046319A (en) | 1997-10-22 | 2000-04-04 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of TNF-α |
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US6007995A (en) | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
| US6013522A (en) | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Smad1 expression |
| US6025198A (en) | 1999-06-25 | 2000-02-15 | Isis Pharmaceuticals Inc. | Antisense modulation of Ship-2 expression |
| AU6343400A (en) * | 1999-07-09 | 2001-01-30 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene |
| US6033910A (en) | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
| WO2001079230A2 (en) * | 2000-04-18 | 2001-10-25 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ugt1a1 gene |
| EP1581648A2 (en) * | 2002-09-09 | 2005-10-05 | Nura, Inc. | G protein coupled receptors and uses thereof |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| JP2007535538A (ja) * | 2004-04-29 | 2007-12-06 | メルク エンド カムパニー インコーポレーテッド | アゼチジングリシン輸送体インヒビター |
| EP2091556B1 (en) | 2006-11-15 | 2018-07-25 | Omeros Corporation | Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease |
| AU2013262709A1 (en) * | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| EP3363902B1 (en) | 2012-12-06 | 2019-11-27 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
| MX2018007674A (es) * | 2015-12-21 | 2018-09-12 | Bayer Oy | Un metodo para la fabricacion de un anillo vaginal. |
| JP7556688B2 (ja) * | 2016-07-28 | 2024-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｇｐｒ１５６変異体及びその使用 |
-
2017
- 2017-07-28 JP JP2019504021A patent/JP7556688B2/ja active Active
- 2017-07-28 NZ NZ751010A patent/NZ751010A/en unknown
- 2017-07-28 AU AU2017302611A patent/AU2017302611B2/en not_active Ceased
- 2017-07-28 DK DK17754224.8T patent/DK3491014T5/da active
- 2017-07-28 CN CN201780048589.4A patent/CN109563516B/zh active Active
- 2017-07-28 US US15/662,689 patent/US10266582B2/en active Active
- 2017-07-28 CA CA3032124A patent/CA3032124A1/en active Pending
- 2017-07-28 WO PCT/US2017/044321 patent/WO2018022967A1/en not_active Ceased
- 2017-07-28 EP EP23162215.0A patent/EP4230648A3/en not_active Withdrawn
- 2017-07-28 KR KR1020247005755A patent/KR20240027874A/ko not_active Ceased
- 2017-07-28 SG SG11201900738YA patent/SG11201900738YA/en unknown
- 2017-07-28 KR KR1020197001965A patent/KR102661616B1/ko active Active
- 2017-07-28 MX MX2019001084A patent/MX2019001084A/es unknown
- 2017-07-28 EP EP17754224.8A patent/EP3491014B1/en active Active
-
2019
- 2019-01-25 MX MX2024013403A patent/MX2024013403A/es unknown
- 2019-01-27 IL IL264473A patent/IL264473A/en unknown
- 2019-03-15 US US16/354,563 patent/US10562953B2/en active Active
-
2020
- 2020-01-03 US US16/733,663 patent/US11155598B2/en not_active Expired - Fee Related
-
2021
- 2021-09-23 US US17/483,047 patent/US20220073589A1/en not_active Abandoned
-
2023
- 2023-02-10 JP JP2023019464A patent/JP2023071704A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019527229A (ja) | 2019-09-26 |
| KR20190034532A (ko) | 2019-04-02 |
| EP4230648A3 (en) | 2023-10-18 |
| EP4230648A2 (en) | 2023-08-23 |
| CN109563516A (zh) | 2019-04-02 |
| DK3491014T3 (da) | 2023-05-30 |
| US10266582B2 (en) | 2019-04-23 |
| CN109563516B (zh) | 2023-10-27 |
| KR102661616B1 (ko) | 2024-04-30 |
| EP3491014A1 (en) | 2019-06-05 |
| US20220073589A1 (en) | 2022-03-10 |
| AU2017302611A1 (en) | 2019-03-14 |
| JP2023071704A (ja) | 2023-05-23 |
| MX2019001084A (es) | 2019-06-10 |
| DK3491014T5 (da) | 2024-09-02 |
| KR20240027874A (ko) | 2024-03-04 |
| US20180030114A1 (en) | 2018-02-01 |
| EP3491014B1 (en) | 2023-04-05 |
| US10562953B2 (en) | 2020-02-18 |
| NZ751010A (en) | 2024-11-29 |
| WO2018022967A1 (en) | 2018-02-01 |
| AU2017302611B2 (en) | 2021-12-09 |
| CA3032124A1 (en) | 2018-02-01 |
| US20200231651A1 (en) | 2020-07-23 |
| JP7556688B2 (ja) | 2024-09-26 |
| MX2024013403A (es) | 2024-12-06 |
| US20190202891A1 (en) | 2019-07-04 |
| IL264473A (en) | 2019-02-28 |
| US11155598B2 (en) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900738YA (en) | Gpr156 variants and uses thereof | |
| SG11201906735RA (en) | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof | |
| SG11201809649WA (en) | Macromolecule analysis employing nucleic acid encoding | |
| SG11201808552XA (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201909203WA (en) | Tissue selective transgene expression | |
| SG11201804162WA (en) | Compositions comprising bacterial strains | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201906264YA (en) | Improved serum albumin binders | |
| SG11201907653QA (en) | Compositions and methods for enhanced gene expression | |
| SG11201903674YA (en) | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof | |
| SG11201900482SA (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
| SG11201807134RA (en) | Transposon system and methods of use | |
| SG11201407789RA (en) | Humanized non-human animals with restricted immunoglobulin heavy chain loci | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201407866XA (en) | Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof |